Antengene receives IND approval for Phase 1 Trial of ATG-101
Category: #health  By Mateen Dalal  Date: 2021-11-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

Antengene receives IND approval for Phase 1 Trial of ATG-101

Antengene Corporation Limited, a leading biopharmaceutical company, has successfully received approval from the US FDA (Food and Drug Administration) for Investigational New Drug (IND) application of ATG-101, a potential treatment for metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma (B-NHL).

The approval for IND will enable Antengene to commence a Phase 1 clinical trial for assessing the security and admissibility of ATG-101 in patients with advanced solid tumors and NHL.

ATG-101 is the first innovative molecule developed in-house with global rights that is entering clinical stage. This is the second monitoring authorization of ATG-101, following HREC (Human Research Ethics Committee) approval and spot beginning for a Phase 1, dose-escalating clinical trial in Australia.

Additionally, this is a noteworthy milestone for Antengene as the first approval for IND in the U.S.

ATG-101 was developed to prevent the binding of immunosuppressive PD-L1/PD-1 and conditionally induce 4-1BB activation, thereby activating anti-tumor immune effectors, with the potential for increased anti-tumor effectiveness and safety.

In GLP toxicological studies, ATG-101 exhibited strong anti-tumor effectiveness in animal models of cancers that progressed on anti-PD-1/L1 therapy, as well as a favorable safety profile.

Dr. Jay Mei, Chairman and CEO of Antengene, said ATG-101 has been developed to offer a new and more effective treatment to patients suffering from solid tumors and NHL who are resistant or refractory to anti-PD-1/PD-L1 therapies.  Approval of the U.S. IND application for ATG-101 is an important breakthrough for Antengene.

Importantly, ATG-101 is also undergoing a Phase I dose-escalating clinical study in Australia, and the company expects to file an IND application in China before the end of the year.

These studies demonstrate Antengene's global execution capabilities and support the company's aim of treating patients beyond borders.

Since in 2017, Antengene has received 17 IND approvals and has submitted 6 NDAs (new drug applications) in multiple markets across Asia Pacific.

Source Credit - https://www.biospace.com/article/releases/antengene-receives-fda-approval-of-ind-for-phase-1-trial-of-atg-101-pd-l1-4-1bb-bispecific-antibody-in-solid-tumors-and-non-hodgkin-lymphoma/?s=74

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Meter nabs $38Mn to scale business & support faster enterprise internet
Meter nabs $38Mn to scale business & support faster enterprise internet
By Mateen Dalal

Meter, Inc., an internet & Wi-Fi infrastructure provider for businesses, has recently announced that it has successfully raised $38 million in a Series B funding round that was headed by Lachy Groom and Sequoia Capital. Industry leaders like D...

MakeMyTrip teams up with banks to offer ‘Book Now Pay Later’ option
MakeMyTrip teams up with banks to offer ‘Book Now Pay Later’ option
By Mateen Dalal

The BNPL (book now pay later) payment has been introduced on MakeMyTrip on bookings for flights, travel, or hotels as well as on the Goibibo app MakeMyTrip, the online travel company, has recently said that it has collaborated with 15 banks, finte...

BlackBerry collabs with Midis Group to expand Cybersecurity biz growth
BlackBerry collabs with Midis Group to expand Cybersecurity biz growth
By Mateen Dalal

BlackBerry Limited, a Canada-based software company focused on cybersecurity, has recently entered into a partnership with Midis Group, a leading technology company offering advanced hardware and software solutions, to expand its market footprint acr...